IL1B and myasthenia gravis: It has been found that the quercetin treatment group was consistent with the tiamulin group, and the serum and lung levels of IL-1β, IL-6, and TNF-α were significantly reduced compared with the MG group in a dose-dependent manner (Figure 4A–F, p < 0.01).